Cleaning - Sub-visible particles - USP 788, EP 2.9.19 - analysis

Microscopic particles invisible during visual inspection accumulate in injectable products and medical devices, creating thrombosis risks, inflammatory responses, and device malfunctions that threaten patient safety with every administration or implantation. Sub-visible particle analysis by light obscuration following Ph. Eur. 2.9.19, USP 788, ISO 21501-3, and AAMI TIR42 provides critical quality assessment for parenteral devices, ophthalmic products, and injectables where particulate contamination creates thrombosis risks, inflammatory responses, and product quality failures threatening patient safety. This high-sensitivity optical technique quantifies particles from 1 to 100 microns extracted from products into particle-free water or isopropanol, detecting contamination invisible to visual inspection but clinically significant at concentrations triggering regulatory limits. Injectable medical devices including prefilled syringes, administration sets, and implantable drug delivery systems require particulate testing demonstrating compliance with pharmacopeial limits protecting patients from particulate embolism, granuloma formation, and device malfunction caused by particle accumulation at critical surfaces. Ophthalmic devices and contact lens products demand extremely low particle limits given eye sensitivity to foreign material, with testing supporting claims of particle-free manufacturing and validating cleaning processes removing manufacturing residues. The methodology's 1 micron resolution detects particles well below visible thresholds, providing sensitive contamination monitoring that identifies process problems - inadequate cleaning, component degradation, packaging failures - before visible particles develop requiring costly investigations and potential recalls. Manufacturers establishing particle specifications for new products use light obscuration data to set realistic limits balancing patient safety against manufacturing capability.

No.
100421
Stage category
Analyses category
Sample type
Finished device, Primary container
Sample requirement (type)
Sterile or non sterile
Sample quantities
1 product, 50 ml
Equipment
Light Obscuration Particle counter
Lead Time Standard (Days)
10
Lead Time Express (Days)
5
Lead Time Super Express (Days)
2
Accredited
Yes
Test facility
In House
Add this test to cart to request an offer.

Do you need some help?

Other similar tests

Ph.Eur. 2.2.44, Ph.Eur. Mono. 0008, Ph.Eur. Mono. 0169, USP 643, EN 1484, ASTM G136-03
Chemistry - TOC - water analysis

Water touches every aspect of pharmaceutical and medical device manufacturing, yet organic contamination invisible to standard testing can compromise products, harbor dangerous biofilms, and signal system failures before they become catastrophic. Total Organic Carbon analysis serves as the cornerstone of water quality assessment in pharmaceutical, medical device, and industrial applications, quantifying organic contamination in water systems critical for manufacturing, production, and environmental monitoring following EN 1484 and ASTM G136-03 standards. The combustion-oxidation method delivers precise measurements with detection limits suitable for ultrapure water validation through process water characterization, enabling comprehensive contamination assessment from pharmaceutical water systems to industrial process monitoring. Critical applications include validation of water treatment systems where TOC trending reveals membrane fouling or resin exhaustion, verification of cleaning processes where organic levels indicate sanitization effectiveness, and environmental compliance monitoring where discharge limits require documented organic content. The analysis supports quality control programs by establishing baseline values that enable detection of system breaches, trending water quality over time to identify gradual degradation suggesting maintenance needs, and correlating organic levels with microbial growth patterns. Particularly valuable for pharmaceutical water systems where organic contamination indicates microbial growth potential, biofilm formation creating endotoxin sources, or system degradation requiring intervention before contamination compromises products. For medical device manufacturers, TOC monitoring validates that rinse water quality supports cleaning validation claims and prevents organic transfer to devices during final processing. Results enable informed decisions about system maintenance timing, process improvements targeting contamination sources, and regulatory compliance strategies supporting USP and Ph. Eur. water specifications that increasingly emphasize organic contamination control.

ISO 10993-12, Ph.Eur. 2.2.44, USP 643, EN 1484
Chemistry - TOC (medical device) - analysis

Manufacturing residues invisible to visual inspection accumulate on medical device surfaces - machining coolants, mold releases, assembly lubricants - creating biocompatibility failures, cytotoxicity surprises, and regulatory obstacles that derail product launches after substantial development investment. Total Organic Carbon analysis for medical devices following the rigorous extraction protocols of ISO 10993-12 ensures that test conditions accurately simulate clinical use while meeting the analytical requirements of EN 1484, Ph. Eur. 2.2.44, and USP <643>. This comprehensive approach has become indispensable for three critical validation scenarios: cleaning validation during manufacturing line qualification where TOC verifies residue removal to safe levels, biocompatibility testing per ISO 10993-1 providing foundational chemical characterization before biological evaluation, and validation of cleaning processes for reusable medical devices according to AAMI ST98 demonstrating consistent organic residue removal. During manufacturing validation, TOC analysis verifies that cleaning processes consistently remove production residues - machining coolants, mold releases, adhesives, and assembly lubricants - to levels that won't compromise biocompatibility or device functionality. The extraction at physiologically relevant temperatures ensures complete recovery of both loosely bound surface contaminants and absorbed organic materials that could leach during clinical use, providing worst-case assessment. For biocompatibility assessment, TOC data provides the foundational chemical characterization required before biological testing, helping predict and interpret cytotoxicity results while supporting toxicological risk assessments per ISO 10993-17. When validating reprocessing procedures for reusable devices, TOC analysis proves that cleaning protocols achieve consistent organic residue removal across different soil challenges and device designs. The quantitative nature enables statistical process validation, demonstrating six-sigma cleaning effectiveness that visual inspection alone cannot provide.

USP 1057, ISO 15883-1, AAMI ST98, Ph.Eur. 2.5.33
Chemistry - Residual proteins - analysis

The reprocessing of surgical instruments and medical devices represents one of healthcare's most critical yet invisible safety processes, where microscopic protein residues harbor deadly prions, viruses, and bacteria that resist standard sterilization. Protein residue analysis conducted according to ISO 15883-1, AAMI ST98, and AAMI ST72 standards serves as the definitive validation method for reusable medical device cleaning, with the BCA assay's sensitivity to microgram-level protein contamination making it the preferred method for validating both manufacturing cleaning processes and hospital reprocessing procedures. Proteins serve as universal markers for inadequate cleaning - where they persist, so do lipids, endotoxins, and viable microorganisms that threaten patient safety. For manufacturing line validation, protein testing confirms that cleaning processes effectively remove biological materials from test soils, manufacturing aids, and handling contamination, particularly critical for devices manufactured in facilities that also process biological materials or use protein-based processing aids. The extraction methodology using Tween-saline solution ensures complete protein solubilization from complex geometries, validating that cleaning reaches lumens, crevices, and textured surfaces where contamination accumulates and standard cleaning struggles to penetrate. In reprocessing validation for surgical instruments and flexible endoscopes, protein analysis provides quantitative proof that manual cleaning, automated washers, and ultrasonic systems achieve consistent results despite variations in soil types, water quality, and operator technique. Regulatory submissions increasingly require protein testing data with defined acceptance criteria - typically less than 6.4 μg/cm² for general surgical instruments or more stringent limits for critical devices contacting sterile tissues or blood. The correlation between protein levels and overall cleaning effectiveness enables scientifically justified acceptance criteria supporting risk-based reprocessing validation.

ISO 15883-1, AAMI ST98
Chemistry - Residual hemoglobin - analysis

Blood contamination on medical devices represents more than aesthetic concern - residual hemoglobin indicates inadequate cleaning that could transmit bloodborne pathogens, trigger inflammatory responses, or harbor prions resistant to standard sterilization. Hemoglobin testing provides specific detection of blood contamination on medical devices, complementing protein analysis with targeted measurement of this clinically relevant marker. Following ISO 15883-1 and AAMI ST98 protocols, the spectrophotometric method at 405nm offers rapid, cost-effective validation of blood removal during cleaning processes, particularly valuable for devices with visible blood exposure during use. The alkaline extraction method solubilizes hemoglobin from dried blood, clots, and protein layers that form on device surfaces during clinical procedures, ensuring detection even when blood desiccates during transport or storage before reprocessing. This targeted approach proves especially useful for surgical instruments, biopsy devices, and blood collection equipment where hemoglobin represents the primary contamination concern and visual correlation enables intuitive interpretation. For manufacturing validation, hemoglobin testing confirms removal of test soils containing blood products, while for reprocessing validation, it demonstrates effective cleaning across different blood exposure scenarios - fresh blood, dried blood, and blood mixed with other surgical soils including tissue and irrigation fluids. The visual correlation between hemoglobin levels and blood contamination makes results intuitive for training cleaning technicians and troubleshooting cleaning failures, enabling immediate feedback about process effectiveness. Lower cost compared to total protein analysis enables more frequent testing during process optimization while maintaining correlation with overall cleaning effectiveness.